Tobacco Smoking and Risk of Second Primary Lung Cancer

• Published in: Journal of thoracic oncology 2021-06, Vol.16 (6), p.968-979
• Main Authors: Aredo, Jacqueline V., Luo, Sophia J., Gardner, Rebecca M., Sanyal, Nilotpal, Choi, Eunji, Hickey, Thomas P., Riley, Thomas L., Huang, Wen-Yi, Kurian, Allison W., Leung, Ann N., Wilkens, Lynne R., Robbins, Hilary A., Riboli, Elio, Kaaks, Rudolf, Tjønneland, Anne, Vermeulen, Roel C.H., Panico, Salvatore, Le Marchand, Loïc, Amos, Christopher I., Hung, Rayjean J., Freedman, Neal D., Johansson, Mattias, Cheng, Iona, Wakelee, Heather A., Han, Summer S.
• Format: Article
• Language: English
• Subjects: Humans; Lung; Lung Neoplasms - epidemiology; Lung Neoplasms - etiology; Male; Neoplasms, Second Primary - epidemiology; Neoplasms, Second Primary - etiology; Prospective Studies; Risk Factors; Screening; Second primary lung cancer; Smoking cessation; Surveillance; Tobacco Smoking
• ISSN: 1556-0864; 1556-1380
• DOI: 10.1016/j.jtho.2021.02.024

Lung cancer survivors are at high risk of developing a second primary lung cancer (SPLC). However, SPLC risk factors have not been established and the impact of tobacco smoking remains controversial. We examined the risk factors for SPLC across multiple epidemiologic cohorts and evaluated the impact of smoking cessation on reducing SPLC risk. We analyzed data from 7059 participants in the Multiethnic Cohort (MEC) diagnosed with an initial primary lung cancer (IPLC) between 1993 and 2017. Cause-specific proportional hazards models estimated SPLC risk. We conducted validation studies using the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (N = 3423 IPLC cases) and European Prospective Investigation into Cancer and Nutrition (N = 4731 IPLC cases) cohorts and pooled the SPLC risk estimates using random effects meta-analysis. Overall, 163 MEC cases (2.3%) developed SPLC. Smoking pack-years (hazard ratio [HR] = 1.18 per 10 pack-years, p < 0.001) and smoking intensity (HR = 1.30 per 10 cigarettes per day, p < 0.001) were significantly associated with increased SPLC risk. Individuals who met the 2013 U.S. Preventive Services Task Force’s screening criteria at IPLC diagnosis also had an increased SPLC risk (HR = 1.92; p < 0.001). Validation studies with the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial and European Prospective Investigation into Cancer and Nutrition revealed consistent results. Meta-analysis yielded pooled HRs of 1.16 per 10 pack-years (pmeta < 0.001), 1.25 per 10 cigarettes per day (pmeta < 0.001), and 1.99 (pmeta < 0.001) for meeting the U.S. Preventive Services Task Force’s criteria. In MEC, smoking cessation after IPLC diagnosis was associated with an 83% reduction in SPLC risk (HR = 0.17; p < 0.001). Tobacco smoking is a risk factor for SPLC. Smoking cessation may reduce the risk of SPLC. Additional strategies for SPLC surveillance and screening are warranted.